Table 3.
Structure | Name | ADP production IC50 (μM) | ADP processing IC50 (μM) | Luminescence detection IC50 (μM) | Solubility | Use/Therapy |
---|---|---|---|---|---|---|
Iriginol hexaaceatate | 1.01±0.04 | N.E.1 | N.E. | Soluble | Semisynthetic compound. Has not been approved as a drug. | |
Hematein | 3.13±0.36 | N.E. | N.E. | Soluble | Anti-inflammatory and anti atherogenic effect in the rabbit model. Tested for the treatment of porphyria. Has not been approved as a drug. | |
Caffeic acid | 6.19.±0.42 | N.E. | N.E. | Soluble | A natural dietary phenolic compound found in plants that is an anti-oxidant. Inhibits the synthesis of leukotrienes. Inhibits carcinogenesis. Has not been approved as a drug. | |
Myricetin | 12.04±2.55 | N.E. | N.E. | Soluble | A naturally occurring flavonol with antioxidant properties. Reduced the risk of pancreatic cancer. | |
Ferulic acid | 13.19±3.90 | N.E. | N.E. | Soluble | Anti neoplastic, choleretic, food preservative. Tested for Alzheimer disease in Japan. Has not been approved as a drug. | |
Quercetin | 59.71±28.56 | N.E. | N.E. | Soluble | Anti tumor agent; induces apoptosis and inhibits synthesis of heat shock proteins. Reduced the risk of pancreatic cancer. | |
Ellagic acid | 0.77±0.06 | Inhibits ATP depletion at higher concentration | N.E.1 | Soluble | Hemostatic, anti neoplastic, anti mutagenic. Anti proliferative and anti oxidant properties in animal models. Has not been approved as a drug. | |
Irigenol | 1.15±0.07 | Inhibits ATP depletion at higher concentration | N.E. | Soluble | Plant product. Has not been approved as a drug. | |
Epicatechin monogallate | 33.66±7.55 | Inhibits ATP depletion at higher concentration | N.E. | Soluble | Antioxidant polyphenol flavinoid. Inhibits Scrapie-associated prion formation. Has not been approved as a drug. | |
Epigallocatechin-3-monogallate | 38.64±24.93 | Inhibits ATP depletion at higher concentration | N.E. | Soluble | Antioxidant polyphenol flavonoid that inhibits telomerase and DNA methyltransferase. Inhibits Scrapie-associated prion formation. Has not been approved as a drug. | |
Tannic acid | 0.77±0.24 | Inhibits ATP depletion at higher concentration | N.E. | Soluble | Nonspecific enzyme/receptor blocker. A specific commercial form of tannin, a polyphenol that is commonly found in topical skin ointments. | |
Theaflavin monogallates | 4.27±0.53 | Inhibits ATP depletion at higher concentration | N.E. | Soluble | Black tea polyphenol. Inhibits growth of cancer cells but not normal cells. Has not been approved as a drug.gua | |
Gentian violet | 12.81±2.57 | 9.47±0.58 | 10.31±1.01 | Soluble | Anti bacterial, anthelmintic effect. Antiseptic to treat fungal infections of the skin. | |
Pararosaniline pamoate | 14.94±4.66 | 9.04±0.82 | 11.64±1.89 | Soluble | Anthelmintic, anti schistosomal drug. | |
Enalapril maleate | N.E.1 | N.E. | N.E. | Soluble | Angiotensin converting enzyme inhibitor. Anti hypertensive drug. | |
Fisetin | N.E. | N.E. | N.E. | Soluble | Anti oxidant, anti inflammatory, and anti carcinogenic effect. Has not been approved as a drug. | |
Hieracin | N.E. | N.E. | N.E. | Soluble | Known guaianolide. Has not been approved as a drug. | |
Iodipamide | N.E. | N.E. | N.E. | Soluble | Radioopaque agent. Used for diagnosis tests for the biliary excretion. | |
Purpurogallin | N.E.1 | N.E. | N.E. | Soluble | Plant phenol. Anti oxidant. Added to fats-oils, fuels, and lubricants as an oxidation retardant. | |
Pyrogallin | N.E. | N.E. | N.E. | Soluble | Anti infectant. Has not been approved as a drug. |
N.E., no effect.